IBDEI2L4 ; ; 04-FEB-2020
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 04, 2020
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,41250,2)
 ;;=^5007067
 ;;^UTILITY(U,$J,358.3,41251,0)
 ;;=I13.10^^152^2031^10
 ;;^UTILITY(U,$J,358.3,41251,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41251,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 1-4 CKD
 ;;^UTILITY(U,$J,358.3,41251,1,4,0)
 ;;=4^I13.10
 ;;^UTILITY(U,$J,358.3,41251,2)
 ;;=^5007068
 ;;^UTILITY(U,$J,358.3,41252,0)
 ;;=I13.11^^152^2031^11
 ;;^UTILITY(U,$J,358.3,41252,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41252,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/o Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,41252,1,4,0)
 ;;=4^I13.11
 ;;^UTILITY(U,$J,358.3,41252,2)
 ;;=^5007069
 ;;^UTILITY(U,$J,358.3,41253,0)
 ;;=I13.2^^152^2031^9
 ;;^UTILITY(U,$J,358.3,41253,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41253,1,3,0)
 ;;=3^Hypertensive HRT & CKD w/ Hrt Fail & Stg 5 CKD/ESRD
 ;;^UTILITY(U,$J,358.3,41253,1,4,0)
 ;;=4^I13.2
 ;;^UTILITY(U,$J,358.3,41253,2)
 ;;=^5007070
 ;;^UTILITY(U,$J,358.3,41254,0)
 ;;=I15.0^^152^2031^15
 ;;^UTILITY(U,$J,358.3,41254,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41254,1,3,0)
 ;;=3^Renovascular Hypertension
 ;;^UTILITY(U,$J,358.3,41254,1,4,0)
 ;;=4^I15.0
 ;;^UTILITY(U,$J,358.3,41254,2)
 ;;=^5007071
 ;;^UTILITY(U,$J,358.3,41255,0)
 ;;=I15.1^^152^2031^3
 ;;^UTILITY(U,$J,358.3,41255,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41255,1,3,0)
 ;;=3^Hypertension Secondary to Oth Renal Disorders
 ;;^UTILITY(U,$J,358.3,41255,1,4,0)
 ;;=4^I15.1
 ;;^UTILITY(U,$J,358.3,41255,2)
 ;;=^5007072
 ;;^UTILITY(U,$J,358.3,41256,0)
 ;;=I15.2^^152^2031^2
 ;;^UTILITY(U,$J,358.3,41256,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41256,1,3,0)
 ;;=3^Hypertension Secondary to Endocrine Disorders
 ;;^UTILITY(U,$J,358.3,41256,1,4,0)
 ;;=4^I15.2
 ;;^UTILITY(U,$J,358.3,41256,2)
 ;;=^5007073
 ;;^UTILITY(U,$J,358.3,41257,0)
 ;;=I15.8^^152^2031^16
 ;;^UTILITY(U,$J,358.3,41257,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41257,1,3,0)
 ;;=3^Secondary Hypertension,Oth
 ;;^UTILITY(U,$J,358.3,41257,1,4,0)
 ;;=4^I15.8
 ;;^UTILITY(U,$J,358.3,41257,2)
 ;;=^5007074
 ;;^UTILITY(U,$J,358.3,41258,0)
 ;;=I15.9^^152^2031^17
 ;;^UTILITY(U,$J,358.3,41258,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41258,1,3,0)
 ;;=3^Secondary Hypertension,Unspec
 ;;^UTILITY(U,$J,358.3,41258,1,4,0)
 ;;=4^I15.9
 ;;^UTILITY(U,$J,358.3,41258,2)
 ;;=^5007075
 ;;^UTILITY(U,$J,358.3,41259,0)
 ;;=I16.0^^152^2031^14
 ;;^UTILITY(U,$J,358.3,41259,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41259,1,3,0)
 ;;=3^Hypertensive Urgency
 ;;^UTILITY(U,$J,358.3,41259,1,4,0)
 ;;=4^I16.0
 ;;^UTILITY(U,$J,358.3,41259,2)
 ;;=^8133013
 ;;^UTILITY(U,$J,358.3,41260,0)
 ;;=I16.1^^152^2031^7
 ;;^UTILITY(U,$J,358.3,41260,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41260,1,3,0)
 ;;=3^Hypertensive Emergency
 ;;^UTILITY(U,$J,358.3,41260,1,4,0)
 ;;=4^I16.1
 ;;^UTILITY(U,$J,358.3,41260,2)
 ;;=^8204721
 ;;^UTILITY(U,$J,358.3,41261,0)
 ;;=I16.9^^152^2031^6
 ;;^UTILITY(U,$J,358.3,41261,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41261,1,3,0)
 ;;=3^Hypertensive Crisis,Unspec
 ;;^UTILITY(U,$J,358.3,41261,1,4,0)
 ;;=4^I16.9
 ;;^UTILITY(U,$J,358.3,41261,2)
 ;;=^5138600
 ;;^UTILITY(U,$J,358.3,41262,0)
 ;;=A07.0^^152^2032^5
 ;;^UTILITY(U,$J,358.3,41262,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,41262,1,3,0)
 ;;=3^Balantidiasis
 ;;^UTILITY(U,$J,358.3,41262,1,4,0)
 ;;=4^A07.0
 ;;^UTILITY(U,$J,358.3,41262,2)
 ;;=^12533
 ;;^UTILITY(U,$J,358.3,41263,0)
 ;;=A07.1^^152^2032^9
